SynthesisBMC neurology2013
A systematic review of biomarkers for disease progression in Parkinson's disease.
Synthesis in BMC neurology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 5 syntheses or guidelines pooled it.
- Plasma alpha-synuclein predicts cognitive impairment in Parkinson's disease: a systematic review and meta-analysis.Journal of neurology · 2025Pooled it
- Dysregulation of melatonin rhythm in Parkinson's and Huntington's disease: a systematic review and meta-analysis.Frontiers in aging neuroscience · 2025Pooled it
- GLP-1 receptor agonists for Parkinson's disease.The Cochrane database of systematic reviews · 2020Pooled it
- A review of clinical trial designs used to detect a disease-modifying effect of drug therapy in Alzheimer's disease and Parkinson's disease.BMC neurology · 2016Pooled it
- Pooled it
- One-Year Substantia NigraMovement disorders : official journal of the Movement Disorder Society · 2026Article
- Plasma Levels of Food-Derived Metabolites as Biomarkers of Parkinson's Disease.International journal of molecular sciences · 2025Article
- Association of cholesterol and glycemic state biomarkers with phenotypic variation and Parkinson's disease progression: The Oxford Discovery cohort.Journal of Parkinson's disease · 2025Article
- Volumetric changes and clinical trajectories in Parkinson's disease: a prospective multicentric study.Journal of neurology · 2023Article
- Neuro-nanotechnology: diagnostic and therapeutic nano-based strategies in applied neuroscience.Biomedical engineering online · 2023Review
- A tissue-fraction estimation-based segmentation method for quantitative dopamine transporter SPECT.Medical physics · 2022Article
- A non-invasive olfactory bulb measure dissociates Parkinson's patients from healthy controls and discloses disease duration.NPJ Parkinson's disease · 2021Article
- Blood biomarkers with Parkinson's disease clusters and prognosis: The oxford discovery cohort.Movement disorders : official journal of the Movement Disorder Society · 2020Article
- Autophagic- and Lysosomal-Related Biomarkers for Parkinson's Disease: Lights and Shadows.Cells · 2019Review
- The Combination of DAT-SPECT, Structural and Diffusion MRI Predicts Clinical Progression in Parkinson's Disease.Frontiers in aging neuroscience · 2019Article
- Longitudinal Progression Markers of Parkinson's Disease: Current View on Structural Imaging.Current neurology and neuroscience reports · 2018Review
- Diagnostic biomarkers for Parkinson's disease at a glance: where are we?Journal of neural transmission (Vienna, Austria : 1996) · 2018Review
- Distinct Role of Striatal Functional Connectivity and Dopaminergic Loss in Parkinson's Symptoms.Frontiers in aging neuroscience · 2017Article
- Article
- The Face Behind the Mask: Can Imaging Help Early Parkinson Diagnosis?Movement disorders clinical practice · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundUsing surrogate biomarkers for disease progression as endpoints in neuroprotective clinical trials may help differentiate symptomatic effects of potential neuroprotective agents from true disease-modifying effects. A systematic review was undertaken to determine what biomarkers for disease progression in Parkinson's disease (PD) exist.
methodsMEDLINE and EMBASE (1950-2010) were searched using five search strategies. Abstracts were assessed to identify papers meriting review in full. Studies of participants with idiopathic PD diagnosed by formal criteria or clearly described clinical means were included. We made no restriction on age, disease duration, drug treatment, or study design. We included studies which attempted to draw associations between any tests used to investigate disease progression and any clinical measures of disease progression. The electronic search was validated by hand-searching the two journals from which most included articles came.
results183 studies were included: 163 (89%) cross-sectional, 20 (11%) longitudinal. The electronic search strategy had a sensitivity of 71.4% (95% CI 51.1-86.0) and a specificity of 97.1% (95% CI 96.5-97.7). In longitudinal studies median follow-up was 2.0 years (IQR 1.1-3.5). Included studies were generally poor quality--cross-sectional with small numbers of participants, applying excessive inclusion/exclusion criteria, with flawed methodologies and simplistic statistical analyses.
conclusionWe found insufficient evidence to recommend the use of any biomarker for disease progression in PD clinical trials, which may simply reflect the poor quality of research in this area. We therefore present a provisional 'roadmap' for conducting future disease progression biomarker studies, and recommend new quality criteria by which future studies may be judged.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.